Efflux-Related Carbapenem Resistance in Acinetobacter baumannii Is Associated with Two-Component Regulatory Efflux Systems' Alteration and Insertion of ΔAbaR25-Type Island Fragment

Int J Mol Sci. 2023 May 31;24(11):9525. doi: 10.3390/ijms24119525.

Abstract

The efflux pumps, beside the class D carbapenem-hydrolysing enzymes (CHLDs), are being increasingly investigated as a mechanism of carbapenem resistance in Acinetobacter baumannii. This study investigates the contribution of efflux mechanism to carbapenem resistance in 61 acquired blaCHDL-genes-carrying A. baumannii clinical strains isolated in Warsaw, Poland. Studies were conducted using phenotypic (susceptibility testing to carbapenems ± efflux pump inhibitors (EPIs)) and molecular (determining expression levels of efflux operon with regulatory-gene and whole genome sequencing (WGS)) methods. EPIs reduced carbapenem resistance of 14/61 isolates. Upregulation (5-67-fold) of adeB was observed together with mutations in the sequences of AdeRS local and of BaeS global regulators in all 15 selected isolates. Long-read WGS of isolate no. AB96 revealed the presence of AbaR25 resistance island and its two disrupted elements: the first contained a duplicate ISAba1-blaOXA-23, and the second was located between adeR and adeA in the efflux operon. This insert was flanked by two copies of ISAba1, and one of them provides a strong promoter for adeABC, elevating the adeB expression levels. Our study for the first time reports the involvement of the insertion of the ΔAbaR25-type resistance island fragment with ISAba1 element upstream the efflux operon in the carbapenem resistance of A. baumannii.

Keywords: AdeABC; EPI; carbapenem resistance; efflux pump; insertion sequence; multidrug resistance; resistance island; two-component regulatory system.

MeSH terms

  • Acinetobacter baumannii* / metabolism
  • Anti-Bacterial Agents* / metabolism
  • Anti-Bacterial Agents* / pharmacology
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Carbapenems / metabolism
  • Carbapenems / pharmacology
  • Drug Resistance, Multiple, Bacterial / genetics
  • Microbial Sensitivity Tests
  • Mutation

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Carbapenems

Grants and funding

This study was partially supported by grant from the Medical University of Warsaw (grant no. FW15/PM1/18) and by the Foundation for the Development of Diagnostics and Therapy, Warsaw, Poland (REGON: 006220910, NIP: 5262173856 and KRS: 0000195643). Moreover, an article processing charge was partially funded by the Medical University of Warsaw and the National Medicines Institute in Warsaw.